First test of new Cancer-Fighting drug combo begins
NCT ID NCT05327946
Summary
This is an early-stage study to find a safe dose of a new immunotherapy drug, BI 770371, given alone or with another immunotherapy called ezabenlimab. It is for adults with advanced solid tumors who have no other effective treatment options left. The main goal is to see how much of the drug combination patients can tolerate and to check for side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Hospitalier de l'Universite de Montreal (CHUM)
Montreal, Quebec, H2X 0A9, Canada
-
Florida Cancer Specialists-Sarasota-61670
Sarasota, Florida, 34232, United States
-
John Theurer Cancer Center
Hackensack, New Jersey, 07601, United States
-
National Cancer Center Hospital
Tokyo, Chuo-ku, 104-0045, Japan
-
National Cancer Center Hospital East
Chiba, Kashiwa, 277-8577, Japan
Conditions
Explore the condition pages connected to this study.